SCHEMBL4199815

SCHEMBL4199815

CCCCCC/C=C\CCCCCCCCCCO[C@H]1C(O)O[C@@H]2COC(C)(C)O[C@H]2[C@@H]1OCC[C@@H](CCCCCCC)OC

nearest known ligand 0.38

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ TLR4 O00206 2/20 0.38
▸ LPAR1 Q92633 2/20 0.33
▸ LPAR3 Q9UBY5 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.30
▸ CNR1 P21554 1/20 0.30
▸ CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199953 0.91 TLR4 (0.34) TLR4
SCHEMBL4203588 0.86 YWHAZ (0.32) TLR4
SCHEMBL4198145 0.86 YWHAZ (0.32) TLR4
SCHEMBL28066867 0.84 GBA1 (0.41) —
SCHEMBL28066822 0.84 GBA1 (0.41) —
SCHEMBL4197555 0.78 YWHAZ (0.32) TLR4
SCHEMBL4196416 0.78 YWHAZ (0.32) TLR4
SCHEMBL4191936 0.78 YWHAZ (0.32) TLR4
SCHEMBL4199994 0.76 SLC2A1 (0.48) TLR4LPAR1LPAR3ALDH1A1CNR1
SCHEMBL4197240 0.75 CA1 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062214-A1 Left-Side Glucose Lipid a Analogue SANKYO COMPANY, LTD. (JP) 2009-03-05 — — US disclosed
EP-1702926-A1 LEVULOSE GLUCOSELIPID A ANALOGUE Sankyo Company, Limited (JP) 2006-09-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062214-A1 Left-Side Glucose Lipid a Analogue SLC2A3, GPR119, SLC2A2 TLR4 294/4885LPAR1 56/4885LPAR3 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback